These findings support a model in which CIP2A overexpression drives metabolic reprogramming in lung cancer through dual modulation of the AKT–AMPK axis, consistent with our observation of reduced p-AMPK and elevated p-AKT in CIP2A-high tumors. This evidence concerns the gene CIP2A and lung carcinoma.